Ipsen S.A. / GENFIT

Primary Biliary Cholangitis (PBC)

130K US cases/yr · $1.2B Global PBC therapeutics market (2024 estimate) · ~30-40% PBC patients with inadequate UDCA response

Disease Overview

Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune cholestatic liver disease characterized by destruction of small intrahepatic bile ducts, leading to cholestasis, hepatic fibrosis, cirrhosis, and ultimately liver failure or transplant if untreated. PBC affects approximately 130,000-150,000 U.S. adults with prevalence of roughly 40 per 100,000, and is overwhelmingly female (~90%) with peak diagnosis in the fifth and sixth decades. The historical first-line therapy ursodeoxycholic acid (UDCA, generic) leaves approximately 30-40% of patients with inadequate biochemical response (defined as elevated alkaline phosphatase >1.67x ULN or persistent bilirubin elevation), placing them at substantially higher risk of disease progression and mortality. Second-line therapy was historically obeticholic acid (Ocaliva, Intercept/Alfasigma) — an FXR agonist approved in 2016 — but Ocaliva carries significant pruritus, lipid abnormalities, and hepatic decompensation warnings that limit its addressable population. Elafibranor (Iqirvo) — a dual PPAR-alpha/delta agonist — is positioned as a differentiated second-line therapy for UDCA-inadequate-response PBC, with mechanism advantages on lipids and pruritus relative to OCA. The asset received FDA accelerated approval June 2024 and is now part of Ipsen's specialty franchise.

Competitive Landscape

The PBC competitive landscape was, until 2024, effectively a one-asset second-line market dominated by Ocaliva (obeticholic acid, Intercept/Alfasigma) — an FXR agonist approved 2016 with peak sales above $400M but persistent pruritus and decompensation safety concerns and a 2023 FDA AdCom that voted against full approval conversion. Elafibranor (Iqirvo, Ipsen via Genfit license) — a dual PPAR-alpha/delta agonist — received FDA accelerated approval in June 2024 based on the ELATIVE Phase 3 trial showing biochemical response in 51% of treated patients vs 4% placebo at week 52, with a meaningfully cleaner pruritus profile than OCA. Seladelpar (Livdelzi, CymaBay/Gilead post-acquisition) — a selective PPAR-delta agonist — received FDA accelerated approval in August 2024 from the RESPONSE Phase 3, creating a direct head-to-head competitor to elafibranor at launch with similar biochemical-response efficacy and similarly favorable pruritus profile. Pipeline assets include FGF19 analogs and additional FXR agonists. UDCA remains universal first-line; the strategic battle for Ipsen is second-line market share against Gilead/Livdelzi and any residual Ocaliva use.